Please login to the form below

Not currently logged in
Email:
Password:

Array appoints Victor Sandor chief medical officer

He joins from Incyte and will replace Michael Needle

Array Biopharma has named Victor Sandor as its new chief medical officer, handing him responsibility for leading clinical, medical and regulatory strategy and operations across its Array portfolio.

This includes the Colorado, US-based company's binimetinic, a MEK inhibitor in phase III trials for ovarian cancer and melanoma, and filanesib, a KSP inhibitor for multiple myeloma.

Sandor said: “I am pleased to join the Array team at such an exciting time in the company's evolution. In addition to the impressive portfolio of clinical stage assets in development by Array's partners, I look forward to focusing on the development of binimetinib and filanesib, which each target patient populations with significant unmet medical need.”

He brings more than a decade of experience in the pharma and biotech industries to the role, and most recently served as senior VP for global clinical development at Incyte Corporation.

Prior to this he has held VP and CMO for oncology positions at Biogen Idec and also worked on oncology product development at AstraZeneca where he played a role in the registration of Arimidex for adjuvant use.

Ron Squarer, CEO at Array Biopharma, said: “Dr Sandor's leadership, experience and vision will strengthen our clinical development efforts as we advance our late stage, wholly-owned assets towards commercialisation.

“With the possible near-term return of binimetinib to Array, his expertise will have significant unmet medical need.”

16th September 2014

From: Research, Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019
International Women's Day has been celebrated since its inception in 1911. But how far have we come?...

Infographics